Strive raised about $55 million this week through its SATA preferred shares program, enough to buy nearly 638 bitcoins. However, the company's ability to continue this funding method depends on its stock price staying above the $100 nominal value. Since the stock fell below $100 from Wednesday onward, new issuances have been halted, limiting further bitcoin purchases. This model, inspired by Strategy's approach, carries risks including increased future dividend obligations and exposure to bitcoin price fluctuations. Strive currently holds over 29,000 bitcoins, but its funding strategy only works if investors buy shares above nominal value.
Strive's Bitcoin financing model is the subject, with Pluang market data providing context. For readers following cryptocurrency trends, here is Pluang's market snapshot as of Oct 11, 2026 11:01 WIB: of 50 major cryptocurrencies priced on Pluang, 16 rose and 33 fell today. Notable movers include SXP (Solar) down 46.27% at Rp37, BAL (Balancer) up 11.14% at Rp16.297, and EOS (EOS.IO) up 8.13% at Rp12.649.
Vencora has acquired CT InsureTech, a leading insurance technology provider with offices in London, Buenos Aires, and Mexico City. This acquisition strengthens Vencora's insurance technology offerings and expands its presence in Latin America and Eur...
Vencora has acquired CT InsureTech, a leading provider of insurance technology and services with offices in London, Buenos Aires, and Mexico City. This acquisition expands Vencora's portfolio and presence in Latin America and the UK, strengthening it...
JELD-WEN Holding, Inc. reported a net loss of $17.2 million in Q3 2026, a significant improvement from a $367.6 million loss a year earlier, driven by tariff refunds, productivity gains, and cost reductions. Net revenues slightly declined by 1.4% to ...
Ethereum has achieved end-to-end formal verification of leanVM, a minimal zero-knowledge virtual machine designed to aggregate post-quantum signatures efficiently. This milestone is part of Ethereum's plan to transition its network to quantum-resista...
Viking Therapeutics, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced its participation in several major healthcare conferences from November to December 2026. The company will engage in fireside chat...
